(OTC Bulletin Board: PWRM) a leading proteomics company,
announced that it has entered into a collaborative research agreement with New
Horizons Diagnostics Corporation for the development of antibody based
diagnostic tests for neurodegenerative disease utilizing the Company's
identified protein biomarkers .
Power3 has discovered a method employing a series of tests for the
differential diagnosis of neurodegenerative diseases utilizing blood serum,
which was co-developed by neurologist Dr.

memantine mimic

New Horizons
Diagnostics' experience and innovative technology have enabled them to become
a leader in assay development.
Paul E.

alexian alzheimers

Any statements in this press release, which are
not statements of historical fact, may be deemed to be forward-looking
statements.
Fibromyalgia is characterized by widespread muscle pain, stiffness and
disturbed sleep. It is
not surprising that since the majority of people with fibromyalgia experience
sleep disorders that they also experience many of the medical problems that
are the result of non-restorative sleep including: excessive fatigue, muscular
pain, cognitive problems, hormonal and chemical abnormalities, mood disorders,
migraine headaches , and high blood pressure. Freiman, president and chief executive officer, said, "This
payment represents the first million dollar plus royalty received under the
terms of our agreement with Merz. We are , of course, pleased by the receipt
of the funds, which reflect the marketing efforts by Forest Laboratories and
Lundbeck.

healingwell progression

New Horizons Diagnostics is a leading
developer and marketer of easy-to-use rapid diagnostic tests and
instrumentation for applications in the clinical, environmental and food
industries . We believe that by using our identified
protein biomarkers for detection of neurodegenerative diseases coupled with
New Horizons Diagnostics' assay expertise and platform, we can collectively
develop a sensitive commercial test that will address critical unmet needs in
diagnostic medicine.fmaware .

alzheimers mimic

Their highly sensitive tests and instrument platforms are
uniquely suited for doctors offices to accelerate the delivery of results and
early treatment. Words such as "will," "expects," "anticipates ," "plans," and
similar expressions are intended to identify these forward-looking statements. Sleep has been at the core of fibromyalgia
research since 1975 when Harvey Moldofsky, MD found that patients with
fibromyalgia have a deficiency in obtaining deep level stage 4 sleep. and
H. We disclaim , however,
any intent or obligation to update these forward-looking statements.

Some other illnesses can mimic symptoms of Alzheimer's disease.

mimic neurologychannel

Power3 has discovered
unique groups of biomarkers whose profiles are relatively sensitive and
specific in distinguishing patients with Amyotrophic Lateral Sclerosis (ALS),
Alzheimer's disease (AD) and Parkinson's disease from each other, as well as
from normal patients and patients with other neuromuscular and neurological
disorders. More than one million people in
the U.

Statement Regarding Chronic Pain and Treatment of Sleep Disorders

Disordered sleep is a very serious and at times debilitating condition.
Patients need accurate information about treatment options, so that together
with their doctor they can make an educated decision about what type of
treatment plan they wish to implement.

dementia neurologychannel

, Neurobiological
Technologies , Inc. (Nasdaq: NTII) today announced that it had received a
royalty payment of $1,122,895 from Merz Pharmaceuticals GmbH (Merz) for sales
of Memantine for the treatment of moderate-to-severe Alzheimer 's disease in
the quarter ended March 31, 2005.

advancements nutrient

Goldknopf, a pioneer of proteomic discovery and Power3 Medical's Chief
Scientific Officer and his team in The Woodlands, Texas.
Lawrence Loomis , President of New Horizons Diagnostics stated, "New
Horizons Diagnostics has been successfully involved in test platform
development before, but none of these projects are as important or timely as
the collaboration with Power3. We are excited to have been chosen
to be part of this elite team to make a new age of diagnostics available.S. have Parkinson's disease and it affects about one in 100 Americans
over the age of 60. On a smaller scale, but equally devastating, 30,000
Americans are afflicted with ALS, with 5,000 new cases annually.

neurological ageless

About Power3 Medical Products
Power3 Medical Products, http://www.

It is characterized by memory loss that worsens over time and the loss of the ability to perform daily tasks;it is ultimately fatal.

dementia ninds

AD affects one in ten people age 65, two in ten people age
75, and four in ten people age 85 and older.
Some have left patients confused and questioning the very medications that
they have already found to be safe and effective. The company is focused on therapies for neurological conditions
that occur in connection with dementia, Alzheimer's disease, ischemic stroke,
neuropathic pain, and brain cancer.

senile ultimately

Stan Appel , Chair of Neurology at
the Methodist Hospital Neurological Institute and Professor of Neurology at
Baylor College of Medicine in Houston, Texas and his team and Dr. The Company's patent-pending technologies are
being used to develop screening and diagnostic tests for the early detection
and treatment of disease.

menopause mercksource

In total, Power3 has identified 34 biomarkers for
neurodegenerative diseases."
New Horizons Diagnostics will utilize specifically tailored monoclonal and
polyclonal antibodies to the biomarkers, which will be incorporated into
immunoassays. These two fundamental
technology platforms are creating families of diagnostic products for the
Company.nhdiag. The
Company operates a state-of-the-art proteomics laboratory in The Woodlands,
Texas. Recent Confusing Reports re: Sleep Medications are Detrimental
to People With Fibromyalgia

ORANGE, Calif. In a recent survey conducted by the National Fibromyalgia
Association people with fibromyalgia were just as, and in some cases even more
distressed by their symptom of disturbed sleep as they were with their symptom
of widespread body pain. NTI receives royalty payments, pursuant to
its strategic research and marketing cooperation agreement with Merz, on sales
of Memantine by Merz and its marketing partners, Forest Laboratories, Inc.

mercksource bupa

With an aging population and new therapies
available, early detection is paramount.

About New Horizons Diagnostics Corporation
New Horizons Diagnostics Corporation is an established privately held
manufacturer and developer of products for the medical, diagnostic,
environmental and food testing markets.
For more information, please visit our website at http://www. is a biotechnology company engaged in
the business of acquiring and developing central nervous system related drug
candidates.

dementia neurosciences

Power3 Medical and New Horizons Diagnostics Sign Research Agreement to Develop Diagnostic for Neurodegenerative Disease

com, is a leading
proteomics company engaged in the discovery of protein footprints, pathways,
and mechanisms of diseases. Power3 assumes no obligation to update forward-looking
statements as a result of new information, future events or otherwise. The Anne McBride Company
T: 281-466 -1600 Tel: 212-983-1702 x207
E: rlevine@annemcbride.

bupa progression

Once the assays are available, New Horizons Diagnostics will
then develop and validate diagnostic tests on their platform, specifically
designed to detect and discriminate among the neurodegenerative diseases. The Company has
developed two core technologies: its SMART (TM) system for rapid
'dot-on-the-membrane' diagnostic testing, and its luminescence detection
system with accompanying portable Bioluminometer.
Education is key and people who are taking or are considering taking sleep
medications should take the time to carefully educate themselves about
possible side effects, only take medications as directed and let their doctor
know immediately about any problems or side effects that they experience.

progression ultimately

Power3 intends to develop a series of tests, which involve monitoring the
concentration of panels of proteins in the blood."
Alzheimer's disease is the most common form of dementia affecting over 4
million Americans. They have had collaborations with
notable government such agencies; NASA, The Department of Defense, The Food
and Drug Administration , and Centers for Disease Control. These forward- looking statements
represent our judgment as of the date of this release.

memantine biweekly

Dr.com

Lundbeck A/S. These funds will assist us in our efforts to advance the
development of Viprinex(TM) and XERECEPT(R) in late-stage clinical trials."

About Neurobiological Technologies, Inc.

Except for the historical information contained herein, the matters
discussed in this press release are forward-looking statements that involve
risks and uncertainties, including risks associated with our dependence on
Merz and its marketing partners, as well as other risks detailed from time to
time in our Securities and Exchange Commission filings. Actual results may
differ materially from those projected.

mcw healingwell

THE WOODLANDS, Texas, Power3 Medical
Products, Inc. The Company's identified protein biomarkers, drug
targets , and diagnostic tests are targeted toward markets with critical unmet
needs in areas such as breast cancer and neurodegenerative disease. Patients reported that disordered sleep (their
inability to fall asleep, stay asleep and achieve deep levels of restorative
sleep) seem to contribute to their symptoms of increased pain, debilitating
fatigue, and forgetfulness.

mercksource nutrient

com.

This press release contains "forward-looking" statements, including
statements related to Power3's plans to pursue development of tests for the
differential diagnosis of neurodegenerative diseases and the commercialization
of Power3's proteomic tests. Unfortunately, recent reports about
sleep disorders have trivialized their impact. Although there is risk
associated with taking any type of medication , and it is imperative that the
public be made aware of these risks, we encourage people who suffer from sleep
disorders to recognize that the cases recently reported in the news are
considered rare and that these medications are widely recognized as safe and
effective by the FDA. RICHMOND , Calif.
Neurobiological Technologies, Inc.

alexian neurosciences

Goldknopf stated, "With New Horizons Diagnostics, we are now
positioned to take our biomarkers into the high throughput immunodiagnostic
test market . Our strategy is to create licensing opportunities with
companies in the diagnostic sector and we look forward to a mutually
beneficial collaboration.

Alzheimer's disease is a type of dementia that usually affects older adults.

givers nutrient

Power3Medical.
There are a number of important factors and uncertainties that could cause
results to differ materially from those indicated by these forward-looking
statements , including risks inherent in research and development activities;
the ability to raise sufficient capital and obtain financing for the
development activities; uncertainties associated with regulatory approvals; as
well as other risks detailed from time to time in Power3's reports filed with
the Securities and Exchange Commission, including its Annual Report on Form
10-KSB for the year ended December 31, 2003, and its reports on Form 10-QSB
and Form 8-K., The following is a statement by
Lynne Matallana, President and Founder, National Fibromyalgia Association:

Fibromyalgia is a complex chronic pain disorder that affects an estimated
10 million people in the United States and 5-7 percent of the world's
population. Although the majority of people affected by fibromyalgia are women
this illness does not discriminate on the basis of sex or age.

Neurobiological Technologies Inc. Receives $1.1 Million Royalty Payment Related to Memantine

ninds alexian

For more information, visit http: //www.org.

memantine alzheimer

Ira L."
Steven Rash, Chairman and Chief Executive Officer of Power3, commented,
"The development of an antibody based, high throughput test is a crucial step
towards the commercialization of our proteomic tests.

Contacts:
Corporate Investor Relations
Steven Rash Rachel Levine
Chairman/CEO Managing Director
Power3 Medical Products, Inc.